SAN DIEGO, Mar 20, 2006 (BUSINESS WIRE) -- Imagenetix Inc. (IAGX) , a company focused on joint health and joint health-related markets, today announced it has commissioned a new multi-site study to measure the effectiveness of its Celadrin(R) oral capsules for improving overall joint health in patients with osteoarthritis of the knee.
The primary purpose of this study is to confirm the positive clinical results, published in 2002 in the internationally acclaimed peer-reviewed Journal of Rheumatology, demonstrating that Celadrin(R) oral capsules improved range of motion and overall function in knee osteoarthritis patients.
The upcoming 60-day study, a double-blind, placebo-controlled trial expected to be completed this summer, will involve 84 patients currently diagnosed with moderate to severe knee osteoarthritis. The patients will be studied at two locations, in Northridge, Calif., and Ellicot City, Md., operated by Medicus Research, a private clinical trials facility.
Dr. Jay Udani, medical director of Medicus as well as medical director of Northridge Hospital Integrative Medicine Program and assistant clinical professor at UCLA School of Medicine, will serve as the study's project manager and principal investigator.
Celadrin(R) is an all-natural proprietary Imagenetix compound that works by supporting the lubrication of joints and enhancing fluids that cushion bones and joints. Clinical research published recently in both Journal of Rheumatology and Journal of Strength & Conditioning Research demonstrated that knee osteoarthritis patients using topical administration of Celadrin(R) cream had significant improvement in knee range of motion, balance, mobility and overall knee function, without side effects.
"We are firmly committed to providing the most complete scientific data regarding the efficacy of our products," said Imagenetix President William P. Spencer. "We look forward to making this data on Celadrin(R) available at the earliest possible opportunity."
Imagenetix Inc. develops, formulates, private-labels, and produces nutritional supplements, over-the-counter topical creams, skin care products and pharmaceuticals for inflammatory-related markets.
Safe Harbor Statement
his document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.